SS-31 (Elamipretide)
A mitochondria-targeting tetrapeptide, FDA-approved in September 2025 for Barth…
The read
What people observed
Every report answers on a 1–5 scale. This is the whole distribution, never an average pretending to be one number, though the average is beside it.
1 · no effect
1
2 · barely
0
3 · modest
3
4 · clearly worked
1
5 · textbook
0
2.8/5
Average reported outcome
80%
Would run it again
5
Reports filed · very early
What it did, and what else showed up
Counts across this compound's reports, never an average. One report can select several answers.
Reported positive outcomes
cardiovascular / circulation
2
faster recovery
1
joint / tendon relief
1
skin / hair
1
cognition
1
Reported side effects
Kept separate from positive outcomes on purpose.
injection-site irritation
2
headache
2
heart rate
2
GI / nausea
1
mood / anxiety
1
How it was run
What people brought it in for, and how long they stayed on it. Intent, not a result or a treatment claim.
How long they ran it
1 wk
1
4 wk
1
8 wk
1
12 wk
1
16 wk+
1
Anecdote, never medical advice.
These are anonymous personal reports on an experimental research compound, not clinical evidence, and they never set the grade. Talk to a licensed clinician before you start, stop, or change a dose.